Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Recommendation of “Hold” by Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been assigned an average rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $185.50.

Several research analysts recently weighed in on the stock. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price target for the company from $25.00 to $18.00 in a report on Friday, August 16th. The Goldman Sachs Group lowered their price objective on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research report on Wednesday, July 17th. Canaccord Genuity Group restated a “buy” rating and set a $13.00 target price on shares of Atara Biotherapeutics in a research report on Tuesday, August 13th. Finally, StockNews.com began coverage on shares of Atara Biotherapeutics in a research report on Wednesday, June 26th. They set a “hold” rating for the company.

Hedge Funds Weigh In On Atara Biotherapeutics

Several institutional investors have recently modified their holdings of ATRA. Delap Wealth Advisory LLC bought a new position in Atara Biotherapeutics during the 1st quarter worth approximately $29,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Atara Biotherapeutics in the second quarter worth $53,000. Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics during the second quarter worth $79,000. BNP Paribas Financial Markets grew its holdings in shares of Atara Biotherapeutics by 29.3% in the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 86,842 shares during the period. Finally, Acadian Asset Management LLC increased its position in shares of Atara Biotherapeutics by 49.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock valued at $1,830,000 after buying an additional 873,133 shares in the last quarter. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock opened at $8.59 on Wednesday. Atara Biotherapeutics has a 52 week low of $4.96 and a 52 week high of $49.00. The stock has a market capitalization of $42.18 million, a PE ratio of -0.16 and a beta of 0.50. The stock’s fifty day moving average is $8.69 and its 200-day moving average is $13.11.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The business had revenue of $28.64 million for the quarter, compared to analysts’ expectations of $48.30 million. As a group, analysts forecast that Atara Biotherapeutics will post -12.09 earnings per share for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.